greeksoup/ stock research
Stock research / United States / GMAB / Year to 31 December 2024

Genmab A/S (GMAB) annual results, year to 31 December 2024: revenue USD 3,121 million, from the 20-F

Genmab A/S files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2024 it reported revenue of USD 3,121 million, up 30.6% on the year before. Its profit was USD 1,133 million, up 79.6%, and diluted earnings per share USD 17.53.

Revenue
USD 3,121 million
+30.6% on the year
FY2023FY2024
Operating margin
31.1%
32.3% a year earlier
FY2023FY2024
Net income
USD 1,133 million
+79.6% on the year
FY2023FY2024
Diluted EPS
USD 17.53
+83.0% on the year
FY2023FY2024

this yearthe year beforeIn US dollars as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toDec 2023Dec 2024
Revenue2,3903,121
Cost of sales33.0143
Research and development1,1071,414
Selling, general and administrative478549
Operating profit772972
Finance costs254291
Profit before tax8171,326
Income tax186193
Profit for the year6311,133
Profit attributable to shareholders6311,133
Filing20-F20-F
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toDec 2023Dec 2024
Diluted EPS9.5817.53
Basic EPS9.6717.66
Filing20-F20-F

USD per ordinary share, as filed.

Cash flow

Year toDec 2023Dec 2024
Cash from operations1,0711,126
Purchase of property, plant and equipment53.027.0
Free cash flow1,0181,099
Cash from investing-185-1,447
Cash from financing-89.0-566
Filing20-F20-F

USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toDec 2023Dec 2024
Funded by
Equity attributable to shareholders4,6875,137
Borrowings, as filed0.00.0
Lease liabilities114144
Other liabilities4311,133
Total equity and liabilities5,2326,414
Owned
Property, plant and equipment142137
Goodwill0.0355
Other intangible assets15.01,728
Cash and cash equivalents2,2041,380
Trade and other receivables733923
Inventories8.09.0
Other assets2,1301,882
Total assets5,2326,414
Filing20-F20-F

USD million, at each fiscal year end.

Ratios on the filed lines

Year toDec 2023Dec 2024
Operating margin32.3%31.1%
Net margin26.4%36.3%
Free cash flow margin42.6%35.2%
Return on year-end equity13.5%22.1%
Effective tax rate22.8%14.6%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 December 2024, filed 17 February 2026: the filing. The figures are in US dollars as filed.